Is 5-amino-1MQ with SLU-PP-332 legal in the United Kingdom?

An oral capsule combining two research chemicals, commonly 50 mg of 5-amino-1MQ with 0.25 mg of SLU-PP-332, a 200 to 1 ratio by mass. Neither compound has ever been given to a human being in a published study. Both literatures are mice, and a common tablet variant adds 125 micrograms of BPC-157 on top, which is an oral route with no evidence for a peptide FDA found had no adequate human data.

This is the exercise-mimetic capsule, sold on the idea that one molecule raises cellular NAD by blocking its disposal and the other switches on the genetic programme exercise switches on. Both ideas come from real laboratories and real papers.

Mechanism: 5-amino-1MQ inhibits nicotinamide N-methyltransferase, the enzyme that methylates nicotinamide for disposal, which in cultured adipocytes raises intracellular NAD+ and lowers 1-methylnicotinamide. SLU-PP-332 agonises estrogen-related receptors alpha, beta and gamma with highest potency at ERR alpha, inducing an acute aerobic exercise transcriptional programme in mouse skeletal muscle.

Regulatory history: Neither compound is approved or is a lawful dietary ingredient. Both are sold as research chemicals in capsule and tablet form, which is a presentation that implies human use.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for 5-amino-1MQ with SLU-PP-332 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.